<DOC>
	<DOCNO>NCT02090413</DOCNO>
	<brief_summary>The primary objective study evaluate whether 150 mg enteric-coated aspirin ( acetylsalicylic acid [ ASA ] ) take twice day ( BID ) dimethyl fumarate ( DMF ) administration 75 mg enteric-coated ASA take daily morning ( QAM ) DMF administration reduces incidence and/or severity flush event subject relapsing-remitting multiple sclerosis ( RRMS ) compare ASA-placebo administer DMF clinical practice set . Secondary objective study : evaluate safety tolerability DMF administer without enteric-coated ASA clinical practice setting ; evaluate impact DMF administration quality life measure Short Form 36 ( SF-36® ) European Quality Life - 5 Dimensions - 5 Levels ( EQ-5D-5L ) questionnaires .</brief_summary>
	<brief_title>Phase 4 Study Effect Aspirin Flushing Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Naïve fumaric acid ester ( e.g . DMF , Fumaderm , compound fumarates ) Diagnosed RRMS satisfies approve therapeutic indication DMF Participants childbearing potential must practice effective contraception willing able continue contraception throughout study Ability complete tolerability scale accurately use electronic diary ( eDiary ) ability complete paper Flushing Diaries Key Inability unwillingness comply study requirement , discretion Investigator , deem unsuitable study participation One major comorbidities , opinion Investigator , may affect outcome study otherwise make subject unsuitable candidate study participation . The prevailing product label DMF ASA use guide Known active malignancy ( subject cutaneous basal cell carcinoma completely excise prior study entry remain eligible ) Chronic use ( ≥7 consecutive day ) ASA nonsteroidal antiinflammatory drug ( NSAID ) containing product within month prior enrollment study A know intolerance ASA Active peptic ulceration history peptic ulceration , hemophilia clot disorder , gout Known hypersensitivity reaction ( e.g. , bronchospasm , rhinitis , urticaria ) response ASA NSAID administration Impaired hepatic renal function , opinion investigator Female subject pregnant , lactate , attempt become pregnant DoubleBlind Period ( first 12 week ) study Currently participate another interventional clinical trial NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>flush</keyword>
	<keyword>aspirin</keyword>
</DOC>